Results for tag: "Granulocyte Colony Stimulating Factors"

Granulocyte Colony Stimulating Factors (G-CSF) are a category of immune modulating drugs specifically designed to encourage the bone marrow to increase the production of neutrophils, a type of white blood cell integral to fighting infection. These drugs have a pivotal role in the treatment of neutropenia, a condition characterized by low levels of neutrophils, commonly seen in patients undergoing chemotherapy for cancer. Neutropenia makes individuals susceptible to potentially severe infections; thus, G-CSF drugs are often prescribed to minimize this risk. In the broader context of immune disorders drugs, G-CSFs represent a focused branch aimed at immunity mediated through the hematologic pathway. These factors not only help in managing cancer-related immune suppression but also are explored for their effectiveness in a variety of other hematological and non-hematological disorders where neutrophil activity is crucial. The relevance of this class of drugs is intricately associated with patient management in oncology and hematologic diseases, with research and development efforts geared towards improving efficacy, patient tolerance, and administration methods. Several companies participate in the market for G-CSF drugs. Among the prominent players are Amgen, which produces Neupogen (filgrastim) and Neulasta (pegfilgrastim), and Novartis with its product Zarzio (filgrastim), a biosimilar of Neupogen. Pfizer also offers a biosimilar, Nivestym (filgrastim-aafi), while Teva Pharmaceuticals Show Less Read more